Tetrandrine(

1
B
A
Tetrandrine(µM) 0 4
5 6 Sorafenib(µM)
4 4 4
4
Tetrandrine(µM) 6 6
6 6
Sorafenib(µM) 0 3
4 5
Cell viability for the combination of sorafenib
and tetrandrine in various concentrations
S 1
2
BEL7402

Dose-response curves and combination index
values (CI ?1 ) showed the synergistic effect of
combination with sorafenib and tetrandrine was
existed
S 2
3
Cell cycle for combination of sorafenib and
tetrandrine showed no significant alteration
S 3
4
Activation of caspase-3 and caspase-9 in BEL7402
cells was determined after treatment with
sorafenib and/or tetrandrine for 24 h
S 4
5
The body weights of nude mice bearing established
HCT116 tumor xenografts
S 5
6
B
A
Cell viability could not be rescued by the
autophagy inhibitor 3-methyladenine (3-MA) or
chloroquine (CQ)
S 6
7
A
TET - -
PD - -
TET - -
PD - -

B
TET - -
SB - -
TET - -
SB - -

Cell viability for combination of tetrandrine and
PD98059 (A) or SB 203580 (B)
S 7
8
C
A
B
HCT116
Bax-/- ST
WT Bax-/-
WTST
Bax
Bax-/-
GAPDH
WT
Intracellular ROS
HCT116 cells with Bax-/- were not sensitive to
the combination treatment with sorafenib and
tetrandrine as the HCT116 wild type cells
S 8